Figure 4.

Neutrophil Ablation Also Inhibits Metastasis in the KPC Model

(A) Kaplan-Meier analysis of survival of KPC mice treated from 10 weeks of age with 2A3 isotype-control antibody (n = 11) or 1A8, anti-Ly6G neutrophil-ablating antibody (n = 15). p Values, log rank test.

(B) Table comparing incidence of metastases in KPC mice treated with 2A3 or 1A8. p Value, chi-square test.

(C and D) IHC on tumors from (C) 2A3- or (D) 1A8-treated mice, for MPO, 1A8, F480, and CD3.

(E) Boxplots showing quantification of IHC in (C) and (D). p Values, Mann-Whitney U test.

(F) IHC for 1A8 on spleens from 2A3- and 1A8-treated mice, quantified on right. p Values, Mann-Whitney U test.

(G) Kaplan-Meier survival analysis of KPC (n = 19, median = 157 days) and KPC Cxcr2^fl/fl mice (n = 28, median = 141 days). p Values, log rank test.

(H) Table comparing incidence of metastases in KPC and KPC Cxcr2^fl/fl mice. p Values, chi-square test.

(I) Boxplots showing quantification of CD3 IHC in tumors from KPC and KPC Cxcr2^fl/fl mice. p Value, Mann-Whitney U test.